Chloe Pasin, Peter Rusert, Daniel Schmidt, Merle Schanz, Nikolas Friedrich, Irene A. Abela, Katharina Kusejko, Cyrille Niklaus, Michèle Sickmann, Jacqueline Weber, Michael Huber, Amapola Manrique, Andri Rauch, Alexandra Calmy, Matthias Cavassini, Marcel Stöckle, Julia Notter, Enos Bernasconi, Dominique L. Braun, Huldrych F. Günthard, Roger D. Kouyos, Alexandra Trkola, the Swiss HIV Cohort Study
{"title":"XbnAb 群体：304 名具有广泛中和 HIV-1 抗体活性的人","authors":"Chloe Pasin, Peter Rusert, Daniel Schmidt, Merle Schanz, Nikolas Friedrich, Irene A. Abela, Katharina Kusejko, Cyrille Niklaus, Michèle Sickmann, Jacqueline Weber, Michael Huber, Amapola Manrique, Andri Rauch, Alexandra Calmy, Matthias Cavassini, Marcel Stöckle, Julia Notter, Enos Bernasconi, Dominique L. Braun, Huldrych F. Günthard, Roger D. Kouyos, Alexandra Trkola, the Swiss HIV Cohort Study","doi":"10.1101/2024.09.13.612733","DOIUrl":null,"url":null,"abstract":"Broadly neutralizing antibodies (bnAbs) recognizing a diversity of HIV-1 strains are widely thought to be essential for an HIV-1 vaccine. Extensive knowledge on bnAbs has been gained from studying natural HIV infection by following bnAb evolution in individual people with HIV (PWH). However, it remains essential to increase knowledge of bnAb responses in large PWH cohorts to assess the feasibility of inducing bnAb activity by vaccination. To allow a systematic analysis, we created the XbnAb cohort, a large bnAb-inducer cohort selected by screening plasma of PWH enrolled in the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI). The XbnAb cohort represents a retrospective, biobank-based cohort comprising data of 304 PWH who developed bnAb activity during HIV-1 infection. Here, we report on the characteristics of the XbnAb cohort and its potential for HIV vaccine research.","PeriodicalId":501182,"journal":{"name":"bioRxiv - Immunology","volume":"65 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The XbnAb Cohort: 304 people with broadly neutralizing antibody activity to HIV-1\",\"authors\":\"Chloe Pasin, Peter Rusert, Daniel Schmidt, Merle Schanz, Nikolas Friedrich, Irene A. Abela, Katharina Kusejko, Cyrille Niklaus, Michèle Sickmann, Jacqueline Weber, Michael Huber, Amapola Manrique, Andri Rauch, Alexandra Calmy, Matthias Cavassini, Marcel Stöckle, Julia Notter, Enos Bernasconi, Dominique L. Braun, Huldrych F. Günthard, Roger D. Kouyos, Alexandra Trkola, the Swiss HIV Cohort Study\",\"doi\":\"10.1101/2024.09.13.612733\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Broadly neutralizing antibodies (bnAbs) recognizing a diversity of HIV-1 strains are widely thought to be essential for an HIV-1 vaccine. Extensive knowledge on bnAbs has been gained from studying natural HIV infection by following bnAb evolution in individual people with HIV (PWH). However, it remains essential to increase knowledge of bnAb responses in large PWH cohorts to assess the feasibility of inducing bnAb activity by vaccination. To allow a systematic analysis, we created the XbnAb cohort, a large bnAb-inducer cohort selected by screening plasma of PWH enrolled in the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI). The XbnAb cohort represents a retrospective, biobank-based cohort comprising data of 304 PWH who developed bnAb activity during HIV-1 infection. Here, we report on the characteristics of the XbnAb cohort and its potential for HIV vaccine research.\",\"PeriodicalId\":501182,\"journal\":{\"name\":\"bioRxiv - Immunology\",\"volume\":\"65 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"bioRxiv - Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.13.612733\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv - Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.13.612733","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The XbnAb Cohort: 304 people with broadly neutralizing antibody activity to HIV-1
Broadly neutralizing antibodies (bnAbs) recognizing a diversity of HIV-1 strains are widely thought to be essential for an HIV-1 vaccine. Extensive knowledge on bnAbs has been gained from studying natural HIV infection by following bnAb evolution in individual people with HIV (PWH). However, it remains essential to increase knowledge of bnAb responses in large PWH cohorts to assess the feasibility of inducing bnAb activity by vaccination. To allow a systematic analysis, we created the XbnAb cohort, a large bnAb-inducer cohort selected by screening plasma of PWH enrolled in the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI). The XbnAb cohort represents a retrospective, biobank-based cohort comprising data of 304 PWH who developed bnAb activity during HIV-1 infection. Here, we report on the characteristics of the XbnAb cohort and its potential for HIV vaccine research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
